ATRA (Atara Biotherapeutics) FFO


ATRA Atara Biotherapeutics Inc ATRA
31 GF Score
Price $10.22
GF Value $1.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Atara Biotherapeutics FFO?

FFO (Funds from operations) only applies to REITs.

ATRA
31GF Score
Atara Biotherapeutics Inc ATRA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Atara Biotherapeutics (ATRA) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of $10.22 is trading 555.1% above its estimated GF Value™ of $1.56. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for ATRA:

  • FFO:
  • GF Value™: $1.56 vs. price of $10.22 (555.1% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atara Biotherapeutics Business Description

Other Exchanges 0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score

Get the complete analysis for ATRA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.22
Price
$1.56
GF Value